NRX Pharmaceuticals (NRXP) Non Operating Income (2017 - 2026)

NRX Pharmaceuticals (NRXP) has 10 years of Non Operating Income data on file, last reported at $3.3 million in Q1 2026.

• On a quarterly basis, Non Operating Income rose 298.92% year-over-year to $3.3 million in Q1 2026; TTM through Mar 2026 was -$7.4 million, a 4.36% increase from a year earlier, with the FY2025 full-year figure at -$12.4 million, down 87.17% from the prior year.
• Non Operating Income for Q1 2026 stood at $3.3 million, down from $5.0 million in the prior quarter.
• Over the last five years, Non Operating Income for NRXP reached as high as $5.0 million in Q4 2025 and fell as low as -$13.9 million in Q2 2025.
• Historically, Non Operating Income has averaged -$794352.9 across 5 years, with a median of -$353000.0 in 2022.
• Across the five-year window, Non Operating Income surged 1845.69% in 2022 and plunged 9081.08% in 2024, its largest moves.
• Year by year, Non Operating Income stood at -$353000.0 in 2022, then surged by 120.96% to $74000.0 in 2023, then plunged by 9081.08% to -$6.6 million in 2024, then soared by 174.99% to $5.0 million in 2025, then plunged by 33.55% to $3.3 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were $3.3 million in Q1 2026, $5.0 million in Q4 2025, and -$1.9 million in Q3 2025.